1000 Participants Needed

Sample Collection Methods for Respiratory Infection Testing

TN
BZ
BK
Overseen ByBrooklin K Zimmerman, MSN
Age: 18+
Sex: Any
Trial Phase: Academic
Sponsor: University of Nebraska
No Placebo GroupAll trial participants will receive the active study treatment (no placebo)

What You Need to Know Before You Apply

What is the purpose of this trial?

This trial tests new, less invasive methods for collecting samples to diagnose respiratory infections like COVID-19. Researchers compare two new devices to the traditional nasopharyngeal swab, which can be uncomfortable and painful. Participants will provide samples using a saliva collection device, a nasopharyngeal wash, and a finger stick for blood (for a COVID-19 antibody test). Those who have already had a nasopharyngeal swab during an emergency department visit might be a good fit for this study. As an unphased trial, this study offers participants the chance to contribute to innovative diagnostic methods that could improve patient comfort and care.

Will I have to stop taking my current medications?

The trial information does not specify whether you need to stop taking your current medications. It seems focused on testing methods rather than medication use.

What prior data suggests that these sample collection methods are safe for respiratory infection testing?

In a previous study, saliva tests, such as those using the Oral Capsule, showed potential for diagnosing COVID-19. However, more research is needed to improve their accuracy. Collecting saliva is generally safe and less uncomfortable than traditional methods.

Research has shown that the finger stick blood method is easy to handle. It requires only a small drop of blood and is commonly used to detect COVID-19 antibodies. This method is popular in at-home test kits and is considered safe.

The passive drool method for collecting saliva is another safe option. Studies suggest that saliva collection effectively checks for COVID-19 antibodies, avoiding the discomfort of deeper nasal swabs.

Lastly, the nasopharyngeal (NP) saline wash is less uncomfortable than traditional swabs. It uses a gentle saline rinse to collect samples. CDC guidelines recommend NP specimen collection as a reliable way to test for respiratory infections.

Overall, these methods are designed to be safer and more comfortable than older techniques, aiming to reduce pain and injury during sample collection.12345

Why are researchers excited about this trial?

Researchers are excited about this trial because it explores innovative ways to collect samples for testing respiratory infections like COVID-19. Unlike traditional methods that often involve deep nasal swabs, these new techniques focus on less invasive options. For example, the Oral Capsule allows saliva collection through chewing, and the passive drool method utilizes a simple straw to collect saliva. Additionally, the NP saline wash uses a gentle saline rinse for sample collection. These methods could make testing more comfortable and accessible, potentially increasing the willingness of individuals to get tested and improving early detection of infections.

What evidence suggests that these sample collection methods are effective for respiratory infection testing?

This trial will compare different sample collection methods for respiratory infection testing. Research has shown that saliva tests are promising for detecting respiratory infections like COVID-19. One study found that saliva tests can serve as a good alternative to the usual nose swabs, which are more uncomfortable. Participants in this trial may use the Oral Capsule, a saliva-based method, which appears effective for accurate detection, though further research is needed for confirmation.

For blood tests, participants may undergo the fingerstick method, which accurately detects COVID-19 antibodies. Studies have found it easy to use and effective in indicating exposure to COVID-19.

The NP saline wash is another method tested in this trial. It uses a gentle saltwater solution to collect samples from the nose. This technique aims to be less uncomfortable while still effectively identifying respiratory viruses.26789

Who Is on the Research Team?

TN

Thanh Nguyen, PhD

Principal Investigator

University of Nebraska

Are You a Good Fit for This Trial?

This trial is for individuals aged 19 or older who are being seen at the UNMC Emergency Department and have a non-research nasopharyngeal swab ordered. There are no other exclusion criteria, so anyone meeting the age requirement in this setting can participate.

Inclusion Criteria

I am 19 or older and had a nasopharyngeal swab test at UNMC.

Exclusion Criteria

None, if the inclusion criterion is met.

Timeline for a Trial Participant

Screening

Participants are screened for eligibility to participate in the trial

2-4 weeks

Specimen Collection

Participants provide four specimens: saliva drool, Oral Capsule saliva, NP wash, and finger stick serum for testing

1 day
1 visit (in-person)

Testing and Analysis

Specimens undergo respiratory pathogen panel PCR testing and COVID-19 antibody testing

1 year

Follow-up

Participants are monitored for safety and effectiveness after specimen collection

4 weeks

What Are the Treatments Tested in This Trial?

Interventions

  • COVID-19 antibody test
  • Respiratory pathogen panel PCR test
Trial Overview The study is testing two new devices for collecting samples to diagnose respiratory infections: a nasopharyngeal wash device and a saliva collection device called the Oral Capsule. These will be compared with traditional swabbing methods to see if they're easier for patients and safer for healthcare workers.
How Is the Trial Designed?
4Treatment groups
Experimental Treatment
Group I: Saliva passive droolExperimental Treatment2 Interventions
Group II: Oral Capsule salivaExperimental Treatment2 Interventions
Group III: NP saline wash by study deviceExperimental Treatment2 Interventions
Group IV: Blood by standard finger stick methodExperimental Treatment1 Intervention

Find a Clinic Near You

Who Is Running the Clinical Trial?

University of Nebraska

Lead Sponsor

Trials
563
Recruited
1,147,000+

Published Research Related to This Trial

Exhaled breath condensate (EBC) as a method for collecting respiratory samples for COVID-19 diagnosis showed a pooled sensitivity of 69.5% and a specificity of 98.3%, indicating it may not be reliable enough compared to the gold standard of nasal swabs.
The study, which included 4 studies with a total of 205 specimens, highlighted significant variability in results and called for more research to better understand the effectiveness of EBC for COVID-19 diagnosis.
Potential Use of Exhaled Breath Condensate for Diagnosis of SARS-CoV-2 Infections: A Systematic Review and Meta-Analysis.Riccò, M., Zaniboni, A., Satta, E., et al.[2022]
A new PCR test for COVID-19 was developed that can process approximately 180 samples per day without needing robotics, making it more accessible for widespread testing.
The test demonstrated high sensitivity and accuracy, comparable to existing clinical diagnostic protocols, and includes a novel internal control that simplifies the testing process by eliminating the need for DNA digestion.
Processing Hundreds of SARS-CoV-2 Samples with an In-House PCR-Based Method without Robotics.Mair, T., Ivankovic, M., Paar, C., et al.[2021]
Multiplex PCR respiratory panels are viewed positively by healthcare experts, with 85% of surveyed sites believing they support accurate diagnoses and 80% indicating they enhance patient care.
Many institutions implement diagnostic stewardship practices, such as structured order sets and restrictions on test ordering, to optimize the use of these panels, suggesting a proactive approach to improve testing effectiveness.
Diagnostic stewardship to support optimal use of multiplex molecular respiratory panels: A survey from the Society for Healthcare Epidemiology of America Research Network.Baghdadi, JD., O'Hara, LM., Johnson, JK., et al.[2023]

Citations

A new testing platform using fingerstick blood for quantitative ...The data presented here demonstrate the efficacy of an easy-to-use fingerstick blood collection method for detecting and monitoring anti-SARS- ...
Evaluation of the practicability of a finger-stick whole-blood ...Data are scarce regarding the performance of the existing serological COVID-19 tests, and to our knowledge this is the first practicability ...
Evaluation of the Panbio™ COVID-19 IgG rapid test device ...In conclusion, the sensitivity, specificity and accuracy of the Panbio™ test from fingerstick capillary whole blood were high. Testing between 22 and 180 days ...
Immune Responses to COVID-19 Infection or VaccinationParticipants will be asked to provide blood samples (either a normal venous blood draw, a few drops of blood obtained with a small finger-stick device, or both) ...
Evaluation of the practicability of a finger-stick whole-blood ...A real-life study has been conducted in order to evaluate the performance of the COVID-PRESTO ® POC test and the results were recently published.
COVID-19 Self-Collected Antibody Test SystemThe COVID-19 Self-Collected Antibody Test System is an enzyme-linked immunosorbent assay. (ELISA) and a blood collection kit intended for qualitative detection ...
COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/ ...The COVID-19 IgG/IgM Rapid Test Cassette (Whole Blood/Serum/Plasma) is a lateral flow immunoassay intended for the qualitative detection and differentiation.
Interim Guidelines for COVID-19 Antibody TestingAntibody POC tests generally are lateral flow devices that detect IgG, IgM, or total antibody in fingerstick whole blood. Laboratory tests use lateral flow, ...
Understanding Antibody Testing for COVID-19 - PMCMore traditional laboratory-based tests may require traditional blood draws, whereas newer systems require only finger prick blood samples.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security